RT Journal Article
SR Electronic
T1 Mapping brain structural differences and neuroreceptor correlates in Parkinson’s disease visual hallucinations: a mega-analysis
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.17.21251558
DO 10.1101/2021.02.17.21251558
A1 Miriam Vignando
A1 Dominic ffytche
A1 Simon Lewis
A1 Phil Hyu Lee
A1 Seok Jong Chung
A1 Rimona S. Weil
A1 Michele T. Hu
A1 Clare E. Mackay
A1 Ludovica Griffanti
A1 Delphine Pins
A1 Kathy Dujardin
A1 Renaud Jardri
A1 John-Paul Taylor
A1 Michael Firbank
A1 Grainne McAlonan
A1 Henry Ka-Fung Mak
A1 Shu Leong Ho
A1 Mitul A Mehta
YR 2021
UL http://medrxiv.org/content/early/2021/02/19/2021.02.17.21251558.abstract
AB Parkinson’s psychosis (PDP) describes a spectrum of symptoms that may arise in Parkinson’s disease (PD) including visual hallucinations (VH). Imaging studies investigating the neural correlates of PDP have been inconsistent in their findings, due to differences in study design and limitations of scale. Here we use empirical Bayes harmonisation to pool together structural imaging data from multiple research groups into a large-scale mega-analysis, allowing us to apply new methodological approaches to identify cortical regions and networks involved in VH and their relation to receptor binding. Differences of cortical thickness and surface area show a wider cortical involvement underlying VH than previously recognised, including primary visual cortex and its surrounds, and the hippocampus, independent of its role in cognitive decline. Structural covariance analyses point to a strong involvement of the attentional control networks in PD-VH, while associations with receptor density maps suggest neurotransmitter loss may drive the cortical changes.Competing Interest StatementDR. Rimona Weil has received speaker honoraria from GE Healthcare. Prof. Hu reports funding/grant support from Parkinson's UK, Oxford NIHR BRC, University of Oxford, CPT, Lab10X, NIHR, Michael J Fox Foundation, H2020 European Union, GE Healthcare and the PSP Association. She also received payment for Advisory Board attendance/consultancy for Biogen, Roche, CuraSen Therapeutics, Evidera, Manus Neurodynamica and the MJFF Digital Health Assessment Board, outside the submitted work. J-P.T. has received speaker honoraria from GE Healthcare and acted as consultant for Kwoya-Kirin and received funding from Sosei-Heptares. These have no association with the present publication. J-P.T reports funding/grant support from Newcastle NHIR BRC based at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. Funding StatementDr. Miriam Vignando was supported by the MRC grant MR/0059311. Prof. John-Paul Taylor and Dr. Firbank study was supported by the Northumberland Tyne and Wear NHS Foundation Trust, and by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre (BRC) in Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University. Prof. Simon Lewis wishes to thank the NHMRC for the Dementia Research Team Grant, NHMRC Project Grant, Parkinson's NSW Seed Grant 2013, NHMRC Investigator grant, NHMRC-ARC Dementia Fellowship, NHMRC Practitioner Fellowship. Prof. Hu, Prof. Mackay and Dr. Griffanti wish to thank the Monument Trust Discovery Award from Parkinson's UK, the MRC Dementias Platform UK and the National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC), and the NIHR Oxford Health BRC. Prof. Seok Jong Chung wishes to thank the National Research Foundation of Korea funded by the Ministry of Education (Grant NRF-2018R1D1A1B07048959). Dr. Rimona Weil wishes to thank the Wellcome Trust and the UCLH Biomedical Research Centre. Prof. Henry Mak wishes to thank the State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the study (LRS-19/20-17680) was given on the 25/03/2020 by King's College London Research Ethics Office, Psychiatry, Nursing and Midwifery (PNM) Research Ethics Panel. The study was subsequently pre-registered on the Open Science Framework site on 04/05/2020 (https://osf.io/nzatk).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDatasets generated during this study will be made available upon publication at the project page on the Open Science Framework https://osf.io/fv2k7/registrations. https://osf.io/fv2k7/registrations